SCHEMBL4086883

SCHEMBL4086883

OC(=S)N1CCN(c2ncnc3[nH]c4ccc(Cl)cc4c23)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP2K7 O14733 3/20 0.52
HPGD P15428 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 1/20 0.48
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PDGFRB P09619 2/20 0.45
KIT P10721 8/20 0.44
PDGFRA P16234 2/20 0.43
RPS6KB1 P23443 3/20 0.43
AURKA O14965 1/20 0.41
CDK1 P06493 1/20 0.41
MAP2K6 P52564 1/20 0.41
AKT1 P31749 1/20 0.41
HRH4 Q9H3N8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4086882 0.85 HPGD (0.52) MAP2K7HPGDSMN1; SMN2GAAKDM4E
SCHEMBL13962111 0.84 PDGFRB (0.53) MAP2K7PDGFRBKITPDGFRAAURKA
SCHEMBL13938416 0.84 PDGFRB (0.53) MAP2K7PDGFRBKITPDGFRAAURKA
SCHEMBL14196561 0.83 PDGFRB (0.55) MAP2K7PDGFRBKITPDGFRAAURKA
SCHEMBL4086517 0.82 MAP2K7 (0.57) MAP2K7HPGDSMN1; SMN2GAAKDM4E
SCHEMBL13938385 0.81 KIT (0.53) HPGDSMN1; SMN2GAALMNAPDGFRB
SCHEMBL13938546 0.80 KIT (0.60) HPGDSMN1; SMN2LMNAMAPTPDGFRB
SCHEMBL13938538 0.80 LMNA (0.58) MAP2K7HPGDSMN1; SMN2GAAALDH1A1
SCHEMBL4082605 0.80 KIT (0.41) MAP2K7KDM4EALDH1A1LMNAMAPT
SCHEMBL13938364 0.79 KIT (0.49) HPGDSMN1; SMN2GAAPDGFRBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029982-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2009-01-29 US disclosed
US-20080207632-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207632-A1 PROTEIN KINASE INHIBITORS ERBB3, ERBB2, AXL MAP2K7 175/4885HPGD 4263/4885SMN1; SMN2 3097/4885
US-20090029982-A1 PROTEIN KINASE INHIBITORS CDK2, PACSIN2, AKT1 MAP2K7 112/4885HPGD 2141/4885SMN1; SMN2 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.